Preparation and testing of bevacizumab radioimmunoconjugates with bismuth-213 and bismuth-205/bismuth-206

Cancer Biology and Therapy

Volumn 7, Issue 10, 2008, Pages 1547-1554

  Abbas Rizvi, Syed M ^a,b   Song, Emma ^a,b   Raja, Chand ^a,b   Beretov, Julia ^a,b   Morgenstern, Alfred ^c   Apostolidis, Christos ^c   Russell, Pamela J ^d   Kearsley, John H ^a,b   Abbas, K ^e   Allen, Barry J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c JOINT RESEARCH CENTRE   (Italy)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e EUROPEAN COMMISSION   (Belgium)

Author keywords

Bevacizumab radioimmunoconjugates; Combination therapy; Efficacy; In vivo stablity; Long half life Bismuth isotopes; Pharmacokinetics; Targerted alpha therapy

Indexed keywords

ANTIBODY CONJUGATE; BEVACIZUMAB; BISMUTH 205; BISMUTH 206; BISMUTH 213; CHELATING AGENT; PENTETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER SIZE; CHELATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG LIVER LEVEL; DRUG QUALITY; DRUG RETENTION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA HALF LIFE; PROSTATE CANCER; REPRODUCIBILITY; SPLEEN; TUMOR GROWTH;

EID: 54349086311     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.10.6538     Document Type: Article

References (39)

1. Presta LG, Chen H, O'Conner SJ, Chisholm V, et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumours and other disorders. Cancer Res 1997; 57:4593-9.
2. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastasis in a preclinical model. The J Urol 1999; 161:960-3.
3. Reese DM, et al. A phase II trial of humanized antivascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001; 3:65-70.
4. Oobleigh MA, et al. A phase I/II dose escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30:117-24.
5. Yang JC, et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-34.
6. Kabbinavar F, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
7. DeVore R, et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/pacililaxal (CP) to CP alone in patients with stage IIIb/IV NSCLC. Pr Am Soc Clin Oncol 2000; 1896.
8. Kozloff M, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRITE). Presented at ASCO 2006.
9. Berry S, et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and Capecitabine for metastatic colorectal cancer - First B E A Trial. Presented at ASCO 2006.
10. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of Capecitabine compared with bevacizumab plus Capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-9.
11. 213Bi labeled PAI-2. Breast Cancer Res Treat 2002; 71:149-59.
12. 213Bi-labeled- Plasminogen Activator Inhibitor-2. Br J Cancer 2003; 88:944-50.
13. Rizvi SMA, Li Y, Song EY, Qu CF, Raja C, Morgenstern A, Apostolidis C, Allen BJ. Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol Ther 2006; 5:386-93.
14. 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 2005; 22:575-86.
15. Rizvi SMA, Sarkar S, Goozee G, Allen BJ. Radioimmunoconjugates for Targeted Alpha Therapy of Malignant Melanoma. Melanoma Res 2000; 10:281-90.
16. Rizvi SMA, Henniker AJ, Goozee G, Allen BJ. Testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. Leukaemia Res 2002; 26:37-43.
17. Rizvi SMA, Allen BJ, Tian Z, Sarkar S. In vitro and preclinical studies of targeted alpha therapy for colorectal cancer. Colorectal Disease 2001; 3:345-53.
18. Rizvi SMA, Qu CF, Song YJ, Raja C, Allen BJ. In vivo Studies of Pharmacokinetics and Efficacy of Bismuth-213 Labeled Anti-melanoma Monoclonal Antibody 9.2.27. Cancer Biology & Therapy 2005; 4:763-8.
19. 213Bi- labeled PAI2 in preclinical targeted alpha therapy of cancer. Cancer Biol Ther 2007; 6:898-904.
20. 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate 2006; 66:1753-67.
21. Song YJ, Qu CF, Rizvi SMA, Li Y, Robertson G, Raja C, Morgenstern A, Apostolidis C, Perkins AC, Allen BJ. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Letters 2006; 234:176-83.
22. Chand R, Peter G, Rizvi SMA, Emma S, Helen G, John T, Anja B, Alfred M, Christos A, John K, Ralph R, Barry JA. Interim analysis of toxicity and response in a Phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007; 6:846-52.
23. Allen BJ, Raja C, Rizvi SMA, Song E, Graham P. Tumour antivascular alpha therapy: A mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol 2007; (in press - Volume 52).
24. Allen BJ, Raja C, Rizvi SMA, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA, Kearsley J. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005; 4:1318-24.
25. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted α therapy. Anal Chem 2005; 77:6288-91.
26. Gordon SM, Cunningham D. Managing patients treated with Bevacizumab combination therapy. Oncology 2005; 69:25-33.
27. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
29. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697-705.
30. Mass RD, Fyfe G, Hambleton J, Kabbinavar F, Hurwitz H, Novotny W, Sarkar S. Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis. J Clin Oncol 2004; 22.
31. Allen BJ, Rizvi SMA, Li Y, Tian Z, Ranson M. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. Crit Rev Oncol/Haematol 2001; 3:139-46.
32. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 prostate cancer cell line and shows anticancer activity in xenograft animal model. Br J Cancer 2002; 86:1197-203.
33. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med 2005; 46:199-204.
34. Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a novel CHX-A″ derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A″-octreotide. J Medicinal Chem 2006; 49:4297-304.
35. Chong HS, Milenic DE, Garmestani K, Brady ED, Arora H, Pfiester C, Brechbiel MW. In vitro and In vivo evaluation of novel ligands for radioimmunotherapy. Nucl Med Biol 2006; 33:459-67.
36. 90Y-CHX-A″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 2005; 11:7080-6.
37. Camphausen K, Sproull M, Tantama S, Venditto V, Sankineni S, Scott T, Brechbiel MW. Evaluation of chelating agents as anti-angiogenic therapy through copper chelation. Bioorg Medicinal Chem 2004; 12:5133-40.
38. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nature Reviews Drug Discovery 2004; 3:488-99.
39. Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Nilsson R, Sandberg BEB, Brechbiel M. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjugate Chem 2002; 13:1079-92.